CA Patent

CA2756347A1 — Atropisomers of 2-purinyl-3-tolyl-quinazolinone derivatives and methods of use

Assigned to Gilead Calistoga LLC · Expires 2010-09-30 · 16y expired

What this patent protects

The invention provides compounds, compositions and methods to treat certain inflammatory conditions and/or oncology by administering a compound that inhibits PD K isoforms, particularly the delta isoform. It further provides specific stereoisomers of a compound useful for these m…

USPTO Abstract

The invention provides compounds, compositions and methods to treat certain inflammatory conditions and/or oncology by administering a compound that inhibits PD K isoforms, particularly the delta isoform. It further provides specific stereoisomers of a compound useful for these methods. In particular, the compound is an optically active atropisomer of 2-((6-amino-9H-purin-9-yl)methyl)-5-methyl-3-o-tolylquinazolin-4(3H)-one.

Drugs covered by this patent

Patent Metadata

Patent number
CA2756347A1
Jurisdiction
CA
Classification
—
Expires
2010-09-30
Drug substance claim
No
Drug product claim
No
Assignee
Gilead Calistoga LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.